Diagnostics News and Research

RSS

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

10 Sep 2009

All Americans should have access to affordable and high quality health care: President of BIO

“BIO shares President Obama's goal of ensuring that all Americans have access to affordable, sustainable, high quality health care. Biotechnology plays an essential role in achieving this goal. Biotechnology expands the boundaries of science by discovering, developing, and delivering innovative and needed medical products to patients.

10 Sep 2009

Second-quarter fiscal 2009 results announced by Rosetta Genomics

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and six months ended June 30, 2009.

9 Sep 2009

Biomagnetics Diagnostics deploys IOBS testing technology

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced its entry into the Integrated Optical Biosensor System (IOBS) market. IOBS are a relatively new classification of pathogen detection equipment which use advanced fiber optic-based technology to detect a wide variety of human and animal pathogens.

9 Sep 2009

Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics’ three currently available diagnostic tests.

8 Sep 2009

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer.

8 Sep 2009

Aptamer nanoflares for molecular detection in living cells

By combining a gold nanoparticle with a unique family of nucleic acids, researchers at Northwestern University have created a new type of intracellular reporting system that with a flash of light reveals the presence and quantity of a wide variety of biologically important molecules. These so-called nanoflares could provide cancer biologists with a highly sensitive method of tracking complex biochemical processes in real time without interfering with those processes.

7 Sep 2009

Quest Diagnostics selected to be part of DJSI World and DJSI North America

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it was again selected to be part of the Dow Jones Sustainability World Indexes and North America Indexes (DJSI World and DJSI North America).

From Quest Diagnostics 5 Sep 2009

New H1N1 Influenza detection test used to diagnose Australia's first swine flu victim

When the first cases of H1N1 Influenza (swine flu) were reported in Mexico in April, UQ researchers got to work developing a test to diagnose the virus.

4 Sep 2009

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009

Covidien to divest three product lines to streamline its portfolio

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced definitive agreements to sell its Sleep Diagnostics and Oxygen Therapy product lines and a proposal to sell its Sleep Therapy product line.

From Chart Industries 4 Sep 2009

Systematic method for improving the stability of antibodies

Researchers at the U.S. Department of Energy's Argonne National Laboratory have developed a systematic method to improve the stability of antibodies. The technique could lead to better biosensors, disease therapeutics and diagnostic reagents and non-laboratory applications, including environmental remediation.

4 Sep 2009

Covidien's Sleep Diagnostic business acquired by Embla

Embla and Covidien have entered into a definitive agreement under which Embla will acquire Covidien's Sleep Diagnostic business. This includes the sleep diagnostic products sold under the Sandman(TM) brand name. Financial terms of the transaction were not disclosed. Completion of the sale is subject to customary closing conditions.

4 Sep 2009

New Technology Showcase highlighting life science technologies to be featured

LifeScience Alley announced today that eight life science organizations from around the United States and Canada will be exhibiting cutting-edge technologies at the association’s Annual Conference on Dec. 9 as part of the New Technology Showcase.

3 Sep 2009

Wellness program helps company control health care costs

"Healthy Quest is designed to focus on health issues that 'drive a lot of costs, and drive a lot of lost productivity,' like obesity, smoking and stress, [Steve Burton, vice president of health and wellness services at Quest Diagnostics] said."

3 Sep 2009

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement to acquire B.R.A.H.M.S. AG for €330 million (approximately $470 million USD). B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

From Thermo Fisher Scientific Inc. 3 Sep 2009

Researchers to analyse nanoparticles

Researchers at Swansea University's Centre for NanoHealth have been awarded £1 million by the Research Councils' Nanoscience through Engineering to Application cross-council programme, led by the Engineering and Physical Science Research Council (EPSRC), to analyse the levels at which nanoparticles can be deemed safe within cells.

3 Sep 2009

Molecular pathology laboratories gear up for swift swine flu detection

Dr. Jan Nowak, President of the Association for Molecular Pathology presented public comments today at the Clinical Laboratory Improvement Advisory Committee meeting.

3 Sep 2009

Arrayit receives patent certification from China

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces that on August 31st, 2009 the company received a patent certificate from the most populous country on the planet, the People's Republic of China. The patent covers Dr. Mark Schena's microarray methods of genotyping multiple patient samples, commonly referred to as Arrayit's "Variation Identification Platform™" (VIP) technology.

2 Sep 2009

Analytical Technologies division of MDS to be acquired by Danaher

Danaher Corporation (NYSE: DHR) today announced that it has signed a definitive agreement with MDS Inc. (TSX: MDS; NYSE: MDZ) to acquire the Analytical Technologies division of MDS, which includes a 50% ownership position in Applied Biosystems/MDS Sciex joint venture ("AB SCIEX"), a mass spectrometry business, and a 100% ownership position in the former Molecular Devices Corporation, a bioresearch and analytical instrumentation company.

From Danaher 2 Sep 2009